The evolution of ideas about medicinal liver damage

Abstract

Medicinal liver damage (LPP) is one of the main undesirable effects of pharmacotherapy. The emergence of new drugs on the pharmaceutical market, an increase in the number of LPP caused by herbal preparations and biologically active additives, as well as the expansion of the market for immunobiological drugs, make drugs the most important etiological factors for liver damage. For timely diagnosis of LPP, it is necessary to take into account the totality of risk factors, among which, in recent years, significant attention has been paid to biomarkers. The choice of tactics for the management of a patient with LPP is determined by the nature and severity of the disease, the characteristics of the use of a potentially hepatotoxic drug and the individual characteristics of the patient. The appointment of drugs with high hepatotoxic potential sometimes requires a preventive prescription of pathogenetic agents. When using drugs with low hepatotoxic potential, individual monitoring of biochemical parameters is recommended.